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Abstract: Set7 is a key regulatory enzyme involved in the methylation of lysine residues of histone
and non-histone proteins. This lysine methyltransferase is induced during stem cell differentiation
and regulates lineage specific gene transcription and cell fate. In this article we discuss recent
experimental evidence identifying regulatory targets under the control of Set7 as well as emerging
evidence of regulation in stem cell differentiation. Furthermore, we discuss the function of non-coding
RNAs regulated by Set7 implicated in cell plasticity.
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1. Introduction
Histone lysine methylation has emerged as a key epigenetic signature in the transcriptional
regulation of gene expression [1]. As such, lysine methyltransferase enzymes catalyse the
methyl-writing ability at specific lysine residues of histone and non-histone proteins and have
important regulatory roles in defining both gene activation and repression. Set7 was originally
identified as mono-methyltransferase with writing ability on lysine 4 of histone H3 (H3K4me1)
and was predominantly associated with open chromatin formation and thus permissive in gene
expression [2,3]. Set7 also could efficiently control transcriptional events independent of histone
modification to directly methylate transcription factors that are recruited at promoters [4]. In fact,
many non-histone targets have been identified that not only belong to a family of transcriptional
factors but also include chromatin modifiers and RNA binding proteins [5,6]. The challenge now
is to understand the diverse substrate specificity of Set7 with that of biological function and one
notable example of this increasing complexity is hyperglycemic memory. Set7 serves as a sensor of
hyperglycemia controlling persistent activation of pro-inflammatory genes in the vasculature [7,8].
The inner working of gene regulation under glucose stimulation is remarkably complex with Set7
playing a critical role in defining the expression of genes implicated in inflammation. Indeed, glucose
stimulation of vascular endothelial cells directionally controls histone and non-histone mediated
mechanisms of regulation by the Set7 enzyme [8]. This broad substrate specificity is as diverse as the
regulatory proteins and the biological actions that are under control. The effectiveness of extracellular
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stimuli to regulate signalling pathways relies on the capacity of Set7 to modify target molecules.
This cellular response is clearly observed during stem cell differentiation as well as early development
of the zygote. Typically, genes involved in the maintenance of pluripotency are downregulated,
whereas those genes that are responsible for cell fate are often upregulated. This regulatory switch
is controlled by chromatin organization and the specific binding of transcription factors that serve
to control gene expression. Moving into lineage specificity and cell fate control, several groups have
recently shown that Set7 expression is increased during stem cell differentiation [9–12], suggesting that
its activity is a critical switch in cell differentiation. As there have been several outstanding articles
that discuss Set7 function in metabolism [13], transcriptional control [6] and genome stability [5,6],
we chose to focus our attention on the recent experimental results that implicate Set7-mediated stem
cell differentiation. In this perspective we discuss some of the conflicting phenotypes that have been
described using Set7 knockout mice studies with the aim to understand the broad functional role of
the enzyme. Finally, we explore the possible role for Set7 in the regulation of transcription factors and
non-coding RNAs (ncRNAs) implicated in embryonic stem cell (ESC) differentiation.
2. Non-Histone Methylation by Set7 and Genetic Set7 Knockout Mouse Studies
The structural specificity of SET domain methyltransferase studies has dramatically expanded
with non-histone substrates for the Set7 methyltransferase. Based on the catalytic domain and crystal
structure, the substrate and product specificities of the Set7 enzyme reveal remarkable plasticity in
binding [4,14,15]. Peptide array experiments assessing methylation show Set7 recognises the sequence
motif: [G/R/H/K/P/S/T]–[K>R]–[S>K/Y/A/R/T/P/N]–K–[Q/N]–[A/Q/G/M/S/P/T/Y/V] in
peptide (target lysine for methylation is underlined) [14]. Because of the broad substrate specificity,
Set7 has a widespread regulatory role in transcriptional signalling [4]. For instance, the stability and
degradation of p53 is regulated in part by Set7-mediated lysine methylation and plays a critical role in
the response to DNA damage [15,16]. While this study went on to show Set7 mediated methylation
of p53 protein, it is also reported that half of the homozygous Set7 knockout (Set7KO) mice had died
during embryogenesis [16] (Table 1).
Table 1. Comparison of the Set7 knockout mouse studies published.
Publication Year KnockoutType
Deletion
Site Knockout Strategy Survival
Other Knockout
Phenotype
Kurash
et al. [16] 2008 Constitutive Exon 2
Insertion of promoter
less LacZ-Neo-poly-A
cassette
Half of Set7 -/-
mice died during
embryogenesis.
Set7KO mice survived
to adulthood appeared
grossly normal. Set7KO
could not induce p53
downstream targets
upon DNA damage.
Lehnertz
et al. [17] 2011 Conditional Exon 4-8
Crossing to
an actin-Flp
deleter strain
Viable with no
gross abnormality
Normal ability to p53
mediated cell cycle
arrest and apoptosis
following genotoxic
stimuli in Set7KO mice
Campaner
et al. [18] 2011 Constitutive Exon 2
Red/ET-based
recombineering
Viable with
normal life span
No increased
predisposition to
tumorigenesis
No effect on p53
dependent cell cycle
arrest and apoptosis
following DNA damage
Oudhoff
et al. [19] 2013 Conditional Exon 2
Intestinal epithelial
cells (IECs) specific
deletion
No overt
phenotype
Shorter and wider
intestinal crypts.
Increase expression of
YAP target genes
in IECs
Elkouris
et al. [20] 2016 Constitutive Exon 4
Crossing to a
CMV-Cre strain
Normal
development
and fertile
Set7KO has a protective
effect against
pulmonary fibrosis
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Independent studies investigating p53-dependant transcriptional regulation show the
homozygous knockout of the Set7 allele in mice are viable without causing marked consequences on
tumor suppressor activity [17,18]. While reasonable explanations to resolve these discordant findings
remain elusive, these studies indicate an important developmental role for Set7 in embryogenesis that
is distinct from its activity in adult tissue. More recent studies using Set7KO mice have found important
roles in the regulation of the pathways such as Hippo/Yes-Associated Protein (YAP) [19], and TGF-β
signalling [20]. Further studies are required to characterize the role of the lysine methyltransferase
during development and in the signalling pathways linked with embryogenesis.
3. Set7 Regulates Stem Cell Differentiation
The transition of stem cells to a more differentiated state depends heavily on the precise programm
of gene expression mediated by the interaction of transcription factors and epigenetic regulators.
Recent studies have shown that Set7 expression is strongly upregulated during differentiation in
myoblast cells [9], embryoid bodies [10], human and mouse ESCs [11,12]. Pluripotent transcription
factors, Oct4 and Sox2 are critical in maintaining ESCs and reprogramming somatic cells into
induced pluripotent stem cells [21]. Set7 methylates Sox2 protein to inhibit transcriptional activity
and induces Sox2 degradation [10]. Indeed, Set7 expression is subject to control by the binding
of Oct4 and Sox2 at its promoter during mouse ESC (mESC) differentiation [12]. These results
suggest that activation of Set7 by degradation of pluripotency factors is important for facilitating
cell differentiation. Set7 is a dynamic protein that determines subcellular localisation of its target
protein(s) by methylation. For example, Set7 is translocated into the nucleus in human endothelial
cells stimulated by hyperglycemia [8] and promotes cytoplasmic retention by monomethylation of
YAP in the Hippo pathway [19]. Monomethylation of pluripotent factor LIN28A by Set7 is specifically
localized in the nucleoli, which prevents nuclear biogenesis of the primary transcript of let-7, thereby
regulating differentiation of human ESCs (hESCs) [22]. Thus, Set7 regulates activity and subcellular
localization of the target proteins in stem cell differentiation.
Knockdown of Set7 (Set7KD) results in differentiation defects in various types of stem cells.
Set7KD hESCs delay differentiation with defects in both the silencing of pluripotent markers and the
induction of differentiation-associated genes [11]. Set7KD myoblast impairs skeletal muscle myocyte
differentiation by loss of interaction with transcriptional factor MyoD protein [9]. Set7KD Sca1+
cells impair smooth muscle (SM) cell differentiation with global downregulation of SM-associated
genes regulated by H3K4me1 as well as interaction with serum response factor (SRF) protein [12].
Therefore Set7 coordinates the expression of downstream factors necessary for differentiation through
methylation of histone and non-histone proteins.
4. Is Set7 Restricted to SM-Associated Gene Regulation?
Transcriptional network analysis has shown that Set7 regulates differentiation-associated genes
in SM, heart, adipose, skeletal muscle and brain [12]. In addition, TF analysis has demonstrated
that Set7 is not restricted to the regulation of tissue-specific TFs (Figure 1A). Knockdown of Set7 in
embryoid bodies have increased expression of ectoderm markers and reduced expression of endoderm
markers [10]. In hESCs, the pluripotent markers such as SOX2 and OCT4 were increased but the genes
associated with liver (HNF4) and blood (SOX6) were decreased by Set7KD during differentiation [11].
These studies suggest that the gene targets of Set7 are dependent on specific extracellular stimuli to
regulate signalling pathways in differentiation.
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Figure 1. Set7 regulates activity of transcriptional factors and the expression of non‐coding RNA in 
mESC differentiation. RNA‐seq data from mESC, Sca1+ cells and Sca1+ Set7KD cells were accessed 
from  GEO  (GSE81830  [12])  and  aligned  to  the  mouse  genome  (mm10,  ensembl  release  77). 
Differential gene expression was determined using edgeR. Two comparisons were performed:  the 
Sca1+  cell differentiation model  in which  Sca1+  cells were  compared  to mESCs,  and  the  Set7KD 
model in which Sca1+ Set7KD cells are compared to Sca1+ cells transfected with non‐target vector. 
(A) Transcription factor (TF) analysis was performed using Gene Set Enrichment Analysis (GSEA) 
combined with TF ChIP‐seq gene sets from mouse cell types derived from the ENCODE project [23]. 
The results are expressed as the Normalised Enrichment Score (NES). A positive NES indicates that 
genes with binding sites for the TF in question are generally increased in expression, while a negative 
NES  indicates  suppression  of  genes with  a TFBS.  (B) The  heatmap  summarises  gene  expression 
profiles of non‐coding RNAs differentially expressed during differentiation and by Set7KD in Sca1+ 
cells, with a False Discovery Rate (FDR) p value < 0.1. 
5. Set7 Regulates the Expression of Differentiation‐associated ncRNA 
MicroRNAs  (miRNAs) are  integral regulatory elements  in  the  transcriptional control of gene 
expression. Because Set7 controls the processing of let‐7 miRNA by methylation of LIN28A in hESCs 
[22], one  can postulate  that Set7 may  regulate other ncRNAs during  stem  cell differentiation. To 
identify ncRNA genes during mESC differentiation we re‐analysed RNA‐seq data  in Set7KD cells 
[12]. The analysis showed 26 ncRNAs differentially expressed in Set7KD Sca1+ cells and many were 
strongly  associated  with  mESC  differentiation.  Indeed,  ncRNAs  known  to  be  induced  during 
development  include H19,  Igf2os  [24], Dnm3os  [25],  2610203C20Rik  [26]  and Hoxaas3  [27] were 
downregulated in Set7KD Sca1+ cells (Figure 1B). While the results require further investigation for 
biological activity the data implicate Set7 in the regulation of ncRNAs during mESC differentiation.   
6. Conclusion and Future Prospects 
Figure 1. Set7 regulates activity of transcriptional factors and the expression of non-coding RNA in
mESC differentiation. RNA-seq data from mESC, Sca1+ cells and Sca1+ Set7KD cells wer access d
from GEO (GSE81830 [12]) and aligned to the mouse genome (mm10, ense bl release 77). Differential
gene expressio was d t rmined using e g R. Two comparisons were performed: the Sca1+ cell
differentiation model in wh ch Sca1+ cells were compared to mESCs, and the Set7KD model in which
Sca1+ Set7KD cells are compared to Sca1+ cells transfected with non-target vector. (A) Tra scription
factor (TF an lysis was perf med using Gene Set En ichment Analysis (GSEA) combined with
TF ChIP-seq gene se s from mouse c ll types derived from the ENCODE pr ject [23]. The results
are expressed as he Normalise Enrichment Score (NES). A positive NES indicate that genes with
binding sit for the TF in question are generally inc as d in expression, while a negative NES
indicates suppression of genes with a TFBS. (B) T e heatmap summarises gene expression profiles of
non-coding RNAs differentially expressed during differentiation and by Set7KD i Sca1+ cells, with
a False Discovery Rate (FDR) p alue < 0.1.
5. Set7 Regulates the Expression of Differentiatio -Ass ci ted ncRNA
MicroRNAs (miRNAs) are integral r ulatory elements in the transcriptional control f gene
expression. Becaus Set7 controls the processing of let-7 miRNA by methylation of LI 28
hESCs , ca postulate that Set7 may regulate other ncRNAs during stem cell differentiation.
To identify ncRNA genes during mESC differentiation we r -an lysed RNA-seq dat in Set7KD
cells [12]. The analysi howed 26 ncRNAs differ ntially expressed in Set7KD Sca1+ cells and many
were strongly associated with mESC differentiation. I dee , ncRNAs know to be induced ring
development include H19, Igf2os [24], Dnm3os [25], 2610203C20Rik [26] and Hoxaas3 [27] were
downregulated in S t7KD Sca1+ cells (Figure 1B). While the results r quire furth r investigation for
biological activity the data implicate Set7 in the regulation of ncRNAs during mESC differentiation.
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6. Conclusions and Future Prospects
Recent studies have unveiled the regulatory machineries of Set7 mediated stem cell differentiation
(Figure 2).
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Figure 2. Set7 mediated  stem cell differentiation. Recent  studies  reported  that Set7  is upregulated 
during stem cell differentiation. Histones and non‐histone proteins modified by Set7 exhibit changes 
in  protein  activity,  stability  and  transcriptional  regulation  of  genes  during  differentiation.  For 
instance,  methylated  Sox2  protein  by  Set7  induces  degradation  of  Sox2  protein  followed  by 
activation  of  the  Set7  gene.  Abundant  Set7  promotes  the  broad  expression  of 
differentiation‐associated  genes.  In  addition,  ncRNAs  regulated  by  Set7  might  be  involved  in 
differentiation and development.   
The  upregulation  of  Set7  might  be  a  critical  switch  facilitating  cell  differentiation  through 
transcriptional  regulation,  activity  and  degradation  of  Set7  target  proteins.  Furthermore,  we 
propose  that  Set7  induces  the  expression  of  ncRNAs  associated  with  development  and 
differentiation.  Little  is known  about  the  regulatory  events, binding  specificity  and dynamics of 
many of the Set7 associated complexes that carry out ncRNA functions. While Set7 has been shown 
to bind RNA [28] and is implicated in its processing [22], the mechanisms regulating these events are 
yet  to  be  fully  elucidated.  Strongly  implicated  but  of  unknown  function  in  differentiation,  the 
potential  involvement  of  Set7  in  the  regulation  of  ncRNAs will  require  sophisticated molecular 
strategies  to assess  transcript recognition and enzymatic  function during stem cell differentiation. 
This  fascinating  link  also  carries  some  important  challenges  to  experimentally  assess  whether 
validated  extracellular  conditions  such  as  hyperglycemia  activates  pro‐inflammatory  ncRNA 
targets.  While  metabolic  memory  has  been  associated  with  H3K4me1  and  the  persistent 
up‐regulation  of  pro‐inflammatory  pathways  in  vascular  cells  [7],  the  way  stem  cells  use  this 
epigenetic  information might determine cell  fate because of  the dramatic changes  in Set7 activity. 
Recent studies have shown that AMI‐5, a non‐selective protein methyltransferase inhibitor enables 
Oct4‐induced  reprogramming of embryonic  fibroblasts  [29]. Since AMI‐5  inhibits  the activities of 
arginine and lysine methyltransferases the regulatory mechanisms involved are yet to be elucidated. 
Because AMI‐5  inhibits  enzyme  activity  in  an AdoMet/SAM  (S‐adenosylmethionine)  competitive 
manner [30], more selective inhibition of Set7 activity could efficiently reprogram somatic cells. In 
partnership  with  Pfizer,  the  Structural  Genomics  Consortium  (SGC)  developed  PFI‐2,  a  highly 
selective  and  cell‐active  inhibitor  of  Set7  [31]. PFI‐2  occupies  the  lysine  binding  site  of  Set7  and 
interacts with the departing methyl group of SAM. Some of the connections between Set7 inhibition 
and stem cell differentiation are starting to be revealed at the molecular level. Studies have shown 
that PFI‐2 delays Oct4 silencing and differentiation of hESCs [11]. More recently, we have shown this 
Figure 2. Set7 mediated stem cell differentiation. Recent studies reported that Set7 is upregulated
during stem cell differentiation. Histones and non-histone proteins modified by Set7 exhibit changes in
protein activity, stability and transcriptional regulation of genes during differentiation. For instance,
methylated Sox2 protein by Set7 induces degradation of Sox2 protein followed by activation of the Set7
gene. Abundant Set7 promotes the broad expression of differentiation-associated genes. In addition,
ncRNAs regulated by Set7 might be involved in differentiation and development.
The upregulation of Set7 might be a critical switch facilitating cell differentiation through
transcriptional regulation, activity and degradation of Set7 target proteins. Furthermore, we propose
that Set7 induces the expression of ncRNAs associated with development and differentiation. Little is
known about the regulatory events, binding specificity and dynamics of many of the Set7 associated
complexes that carry out ncRNA functions. While Set7 has been shown to bind RNA [28] and is
implicated in its processing [22], the mechanisms regulating these events are yet to be fully elucidated.
Strongly implicated but of unknown function in differentiation, the potential involvement of Set7
in the regulation of ncRNAs will require sophisticated molecular strategies to assess transcript
recognition and enzymatic function during stem cell differentiation. This fascinating link also
carries some important challenges to experimentally assess whether validated extracellular conditions
such as hyperglycemia activates pro-inflammatory ncRNA targets. While metabolic memory has
been associated with H3K4me1 and the persistent up-regulation of pro-inflammatory pathways
in vascular cells [7], the way stem cells use this epigenetic information might determine cell fate
because of the dramatic changes in Set7 activity. Recent studies have shown that AMI-5, a non-selective
protein methyltransferase inhibitor enables Oct4-induced reprogramming of embryonic fibroblasts [29].
Since AMI-5 inhibits the activities of arginine and lysine methyltransferases the regulatory mechanisms
involved are yet to be elucidated. Because AMI-5 inhibits enzyme activity in an AdoMet/SAM
(S-adenosylmethionine) competitive manner [30], more selective inhibition of Set7 activity could
efficiently reprogram somatic cells. In partnership with Pfizer, the Structural Genomics Consortium
(SGC) developed PFI-2, a highly selective and cell-active inhibitor of Set7 [31]. PFI-2 occupies the lysine
binding site of Set7 and interacts with the departing methyl group of SAM. Some of the connections
between Set7 inhibition and stem cell differentiation are starting to be revealed at the molecular level.
Studies have shown that PFI-2 delays Oct4 silencing and differentiation of hESCs [11]. More recently,
Non-coding RNA 2016, 2, 14 6 of 8
we have shown this pharmacological inhibitor reduces the expression of SM-associated genes [12].
While these experiments suggest Set7 methyltransferase initiates or promotes cell determination, the
challenge now will be to experimentally assess whether PFI-2 perturbs epigenetic memory during
stem cell plasticity.
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Abbreviations
The following abbreviations are used in this manuscript:
Set7 SET domain containing lysine methyltransferase 7
H3K4me1 Histone 3 lysine 4 monomethylation
TFs Transcriptional Factors
ncRNA non-coding RNA
ESC Embryonic Stem Cell
KO Knock Out
YAP Yes-Associated Protein
TGFß Transforming Growth Factor beta
Sox2 Sry box-containing gene 2
Oct4 Octamer-binding transcriptional factor 4
LIN28A Lin-28 Homolog A
KD Knock Down
RNA-Seq RNA Sequencing
let-7 Lethal-7
MYOD Myogenic differentiation protein
SM Smooth Muscle
SRF Serum Response Factor
HNF4 Hepatocyte Nuclear Factor 4
miRNA microRNA
Sca1 Stem cell antigen 1
Igf2os Insulin-like growth factor 2, opposite strand
Dnm3os Dynamin 3, Opposite Strand
Hoxaas3 HOXA Cluster Antisense RNA 3
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